Treatment with the dipeptidyl peptidase-1 inhibitor brensocatib increases the antimicrobial peptide secretory leukocyte peptidase inhibitor (SLPI) in patients with bronchiectasis: results from the WILLOW trial
Lídia Perea(Hospital Clínic de Barcelona), James D. Chalmers(University of Dundee), Oriol Sibila(Hospital Clínic de Barcelona), Ariel Teper(Insmed (United States)), Amelia Shoemark(University of Dundee), Carlos Fernández‐Peña(Insmed (United States)), Emma Johnson(University of Dundee), Kevin C. Mange(Insmed (United States)), Holly R. Keir(University of Dundee)
Cited by 0
Related Papers
European Respiratory Society guidelines for the management of adult bronchiectasis
|European Respiratory Journal|2017|1.3k
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
|Annals of the American Thoracic Society|2018|723
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
|Intensive Care Medicine|2023|289
Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals
|Critical Care Medicine|2020|285
Anti-Müllerian Hormone Is a Marker of Gonadotoxicity in Pre- and Postpubertal Girls Treated for Cancer: A Prospective Study
|The Journal of Clinical Endocrinology & Metabolism|2012|202